Brief: Probi: Clinical Trial Confirms Immune Enhancing Impact Of Probi Defendum
Feb 6 (Reuters) - PROBI PROB.ST :
* LARGEST CLINICAL TRIAL CONFIRMS THE IMMUNE ENHANCING
IMPACT OF
PROBI DEFENDUM AND SHEDS NEW LIGHT ON THE MECHANISM
* RESULTS FROM STUDY SHOW THAT PROBI DEFENDUM
SIGNIFICANTLY
DECREASES RECURRENT COMMON COLDS
Source text for Eikon: ID:nWkr5LXZ98
Further company coverage: PROB.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Probi AB
See all newsBrief: Probi To Delist, Last Trading Day Is Feb 12, 2025
Brief: Probi Applies For Delisting And Convenes An Extraordinary General Meeting
Brief: Probi Says Independent Bid Committee Of Co Recommends Shareholders To Accept Cash-Based Public Takeover Offer Submitted By Symrise AG
Probi shares surge in line with premium after Symrise buyout offer
Brief: Symrise Announces Public Offer To Shareholders Of Probi To Tender All Shares